Galmed & Tissue Dynamics Unveil New Cardiac Fibrosis Pathway, Advance Aramchol Towards IND

summarizeSummary

Galmed Pharmaceuticals announced positive preclinical results from its collaboration with Tissue Dynamics, identifying a new metabolic pathway for cardiac fibrosis and demonstrating Aramchol's efficacy in human cardiac organoids, leading to a new patent filing and plans for IND-enabling activities.

check_boxKey Events · Product Development and Regulatory · GLMD

• New Metabolic Pathway Discovered

  Galmed and Tissue Dynamics identified a previously unrecognized metabolic mechanism driving cardiac fibrosis and heart failure using human cardiac organoid models.

• Aramchol Combination Efficacy

  A combination of Aramchol Meglumine and a selective PPARα agonist reduced fibrotic burden by approximately 4-fold (p<0.001) in inflammatory human cardiac organoids, while preserving cardiac muscle integrity.

• Pipeline Advancement for Cardiac Fibrosis

  Based on these preclinical findings, a new patent application has been filed, and preparations are underway to support future IND-enabling activities for Aramchol in cardiac fibrosis.

auto_awesomeAnalysis · GLMD · Life Sciences

This filing announces significant preclinical results from Galmed's collaboration with Tissue Dynamics, identifying a previously unrecognized metabolic pathway for cardiac fibrosis and heart failure. The study demonstrated that a combination of Galmed's lead compound, Aramchol Meglumine, and a PPARα agonist reduced fibrotic burden by approximately four-fold in human cardiac organoids. This discovery, coupled with a new patent application and plans for IND-enabling activities, represents a material advancement for Galmed's pipeline diversification into cardiometabolic indications, potentially opening a new therapeutic avenue for Aramchol.